Carlos Iribarren to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Carlos Iribarren has written about Randomized Controlled Trials as Topic.
Connection Strength
0.126
-
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 05; 139(5):1678-1680.
Score: 0.126